Published in Cancer Causes Control on April 30, 2010
Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial. Prostate (2015) 0.91
Dietary polyphenols in prevention and treatment of prostate cancer. Int J Mol Sci (2015) 0.89
Dietary antioxidants and prostate cancer: a review. Nutr Cancer (2013) 0.89
Nutrigenetics, nutrigenomics, and selenium. Front Genet (2011) 0.81
Association of interleukin-6 (-174 G/C) polymorphism with the prostate cancer risk: A meta-analysis. Biomed Rep (2014) 0.79
Dietary Total Antioxidant Capacity is Inversely Associated with Prostate Cancer Aggressiveness in a Population-Based Study. Nutr Cancer (2016) 0.75
Meta-analysis of the role of IL-6 rs1800795 polymorphism in the susceptibility to prostate cancer: Evidence based on 17 studies. Medicine (Baltimore) (2017) 0.75
Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial. Prostate (2017) 0.75
Increased dietary and circulating lycopene are associated with reduced prostate cancer risk: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis (2017) 0.75
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08
Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science (1992) 7.92
Retracted XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors. Proc Natl Acad Sci U S A (2009) 6.72
Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev (2002) 5.04
Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol (1999) 4.85
Epidemiology of inflammation and prostate cancer. J Urol (2004) 2.76
Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology (2002) 2.60
Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax (2000) 2.49
The role of inflammation in the pathogenesis of prostate cancer. J Urol (2004) 2.29
Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res (2000) 2.22
Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res (2002) 2.09
Epidemiologic association between prostatitis and prostate cancer. Urology (2002) 2.05
Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Res (2005) 1.98
Cytokine gene polymorphism in human disease: on-line databases, supplement 1. Genes Immun (2001) 1.94
Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology (2005) 1.67
Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res (2006) 1.52
Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice. Neoplasia (2001) 1.52
Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer (2004) 1.44
Individual carotenoid concentrations in adipose tissue and plasma as biomarkers of dietary intake. Am J Clin Nutr (2002) 1.37
Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality. Int J Cancer (2009) 1.29
Molecular pathology of prostate cancer. J Clin Pathol (2005) 1.22
Associations between hOGG1 sequence variants and prostate cancer susceptibility. Cancer Res (2002) 1.17
C-reactive protein, interleukin-6, and prostate cancer risk in men aged 65 years and older. Cancer Causes Control (2009) 1.13
COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br J Cancer (2007) 1.11
Adipokine genes and prostate cancer risk. Int J Cancer (2009) 1.10
Differences in base excision repair capacity may modulate the effect of dietary antioxidant intake on prostate cancer risk: an example of polymorphisms in the XRCC1 gene. Cancer Epidemiol Biomarkers Prev (2002) 1.09
Polymorphisms in hOGG1 and XRCC1 and risk of prostate cancer: effects modified by plasma antioxidants. Urology (2009) 1.08
Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. Urology (1999) 1.04
Reported effects of long-term freezer storage on concentrations of retinol, beta-carotene, and alpha-tocopherol in serum or plasma summarized. Clin Chem (1993) 1.03
Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. BMC Cancer (2008) 0.99
CYP3A43 Pro(340)Ala polymorphism and prostate cancer risk in African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev (2005) 0.96
TNF polymorphisms and prostate cancer risk. Prostate (2008) 0.95
Platelet 12-lipoxygenase Arg261Gln polymorphism: functional characterization and association with risk of esophageal squamous cell carcinoma in combination with COX-2 polymorphisms. Pharmacogenet Genomics (2007) 0.89
Plasma carotenoids and prostate cancer: a population-based case-control study in Arkansas. Nutr Cancer (2007) 0.88
Interleukin-6 sequence variants are not associated with prostate cancer risk. Cancer Epidemiol Biomarkers Prev (2004) 0.87
Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol (2007) 3.39
Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat (2005) 2.75
NAT2 slow acetylation and bladder cancer in workers exposed to benzidine. Int J Cancer (2006) 2.16
Trends in mortality from cancers of the breast, colon, prostate, esophagus, and stomach in East Asia: role of nutrition transition. Eur J Cancer Prev (2012) 1.73
The UGT2B17 gene deletion polymorphism and risk of prostate cancer. A case-control study in Caucasians. Cancer Detect Prev (2007) 1.69
Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology (2005) 1.67
Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. J Natl Cancer Inst (2002) 1.58
Identification of aminobiphenyl derivatives in commercial hair dyes. Chem Res Toxicol (2003) 1.58
Meat intake and cooking techniques: associations with pancreatic cancer. Mutat Res (2002) 1.57
p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity. J Natl Cancer Inst (2002) 1.56
Extensive somatic mitochondrial mutations in primary prostate cancer using laser capture microdissection. Cancer Res (2002) 1.53
Synergic effect of polymorphisms in ERCC6 5' flanking region and complement factor H on age-related macular degeneration predisposition. Proc Natl Acad Sci U S A (2006) 1.52
Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men. Cancer Epidemiol Biomarkers Prev (2006) 1.45
Analysis of total meat intake and exposure to individual heterocyclic amines in a case-control study of colorectal cancer: contribution of metabolic variation to risk. Mutat Res (2002) 1.44
Genetic polymorphisms in heterocyclic amine metabolism and risk of colorectal adenomas. Pharmacogenetics (2002) 1.35
Increased distributional variance of mitochondrial DNA content associated with prostate cancer cells as compared with normal prostate cells. Prostate (2008) 1.29
DNA supercoiling suppresses real-time PCR: a new approach to the quantification of mitochondrial DNA damage and repair. Nucleic Acids Res (2007) 1.23
Dietary intake of heterocyclic amines and benzo(a)pyrene: associations with pancreatic cancer. Cancer Epidemiol Biomarkers Prev (2005) 1.23
Associations between catalase phenotype and genotype: modification by epidemiologic factors. Cancer Epidemiol Biomarkers Prev (2006) 1.14
Human alpha class glutathione S-transferases: genetic polymorphism, expression, and susceptibility to disease. Methods Enzymol (2005) 1.13
Detoxification of electrophilic compounds by glutathione S-transferase catalysis: determinants of individual response to chemical carcinogens and chemotherapeutic drugs? Biofactors (2003) 1.12
Association of SULT1A1 phenotype and genotype with prostate cancer risk in African-Americans and Caucasians. Cancer Epidemiol Biomarkers Prev (2004) 1.09
Polymorphisms in hOGG1 and XRCC1 and risk of prostate cancer: effects modified by plasma antioxidants. Urology (2009) 1.08
Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment. Int J Cancer (2003) 1.07
Processed meat intake, CYP2A6 activity and risk of colorectal adenoma. Carcinogenesis (2007) 1.07
Induction of cell proliferation and survival genes by estradiol-repressed microRNAs in breast cancer cells. BMC Cancer (2012) 1.02
Hair dye use, meat intake, and tobacco exposure and presence of carcinogen-DNA adducts in exfoliated breast ductal epithelial cells. Arch Biochem Biophys (2007) 1.02
Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype. Pharmacogenet Genomics (2006) 1.02
Mitochondrial mutagenesis and oxidative stress in human prostate cancer. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev (2004) 1.02
Expression of cytochromes P450 and glutathione S-transferases in human prostate, and the potential for activation of heterocyclic amine carcinogens via acetyl-coA-, PAPS- and ATP-dependent pathways. Int J Cancer (2005) 1.01
Physical activity, diet, and pancreatic cancer: a population-based, case-control study in Minnesota. Nutr Cancer (2009) 1.00
Functional genetic variants in the 3'-untranslated region of sulfotransferase isoform 1A1 (SULT1A1) and their effect on enzymatic activity. Toxicol Sci (2010) 1.00
Evaluation of 4-aminobiphenyl-DNA adducts in human breast cancer: the influence of tobacco smoke. Carcinogenesis (2003) 1.00
The urinary metabolite profile of the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine is predictive of colon DNA adducts after a low-dose exposure in humans. Cancer Res (2006) 1.00
Simultaneous generation of multiple mitochondrial DNA mutations in human prostate tumors suggests mitochondrial hyper-mutagenesis. Carcinogenesis (2003) 0.98
CYP2A13 expressed in human bladder metabolically activates 4-aminobiphenyl. Int J Cancer (2006) 0.97
Identification of carcinogen DNA adducts in human saliva by linear quadrupole ion trap/multistage tandem mass spectrometry. Chem Res Toxicol (2010) 0.97
CYP3A43 Pro(340)Ala polymorphism and prostate cancer risk in African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev (2005) 0.96
Common genetic polymorphisms in the 5'-flanking region of the SULT1A1 gene: haplotypes and their association with platelet enzymatic activity. Pharmacogenet Genomics (2005) 0.95
Novel markers of susceptibility to carcinogens in diet: associations with colorectal cancer. Toxicology (2002) 0.95
A new clue to glaucoma pathogenesis. Am J Med (2003) 0.94
Cystine-glutamate transporter SLC7A11 mediates resistance to geldanamycin but not to 17-(allylamino)-17-demethoxygeldanamycin. Mol Pharmacol (2007) 0.94
Evidence for the presence of mutagenic arylamines in human breast milk and DNA adducts in exfoliated breast ductal epithelial cells. Environ Mol Mutagen (2002) 0.94
The differential effect of NAT2 variant alleles permits refinement in phenotype inference and identifies a very slow acetylation genotype. PLoS One (2012) 0.92
SNPs, haplotypes, and cancer: applications in molecular epidemiology. Cancer Epidemiol Biomarkers Prev (2004) 0.91
Phenotypic CYP2A6 variation and the risk of pancreatic cancer. JOP (2009) 0.90
Human glutathione S-transferase A2 polymorphisms: variant expression, distribution in prostate cancer cases/controls and a novel form. Pharmacogenetics (2004) 0.90
Association of demographic and treatment variables in long-term colon cancer survival. Surg Innov (2008) 0.89
Plasma carotenoids and prostate cancer: a population-based case-control study in Arkansas. Nutr Cancer (2007) 0.88
A variant of the Cockayne syndrome B gene ERCC6 confers risk of lung cancer. Hum Mutat (2008) 0.88
Sulfation of fulvestrant by human liver cytosols and recombinant SULT1A1 and SULT1E1. Pharmgenomics Pers Med (2011) 0.88
Sulfation of 4-hydroxy toremifene: individual variability, isoform specificity, and contribution to toremifene pharmacogenomics. Drug Metab Dispos (2012) 0.87
A comprehensive approach to the profiling of the cooked meat carcinogens 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, and their metabolites in human urine. Chem Res Toxicol (2010) 0.87
Formation and reduction of aryl and heterocyclic nitroso compounds and significance in the flux of hydroxylamines. Chem Res Toxicol (2004) 0.86
Interindividual variation and organ-specific patterns of glutathione S-transferase alpha, mu, and pi expression in gastrointestinal tract mucosa of normal individuals. Arch Biochem Biophys (2002) 0.86
Carcinogenesis of the food mutagen PhIP in mice is independent of CYP1A2. Carcinogenesis (2003) 0.85
A modified host cell reactivation assay to measure DNA repair capacity for removing 4-aminobiphenyl adducts: a pilot study of bladder cancer. Cancer Epidemiol Biomarkers Prev (2005) 0.85
Lack of association between Caucasian lung cancer risk and O6-methylguanine-DNA methyltransferase-codon 178 genetic polymorphism. Lung Cancer (2004) 0.85
Sulfotransferase 4A1. Int J Biochem Cell Biol (2007) 0.85
Sequence variants in antioxidant defense and DNA repair genes, dietary antioxidants, and pancreatic cancer risk. Int J Mol Epidemiol Genet (2011) 0.85
Potential chemoprotective effects of the coffee components kahweol and cafestol palmitates via modification of hepatic N-acetyltransferase and glutathione S-transferase activities. Environ Mol Mutagen (2004) 0.85
Variation in cyclooxygenase expression levels within the colorectum. Mol Carcinog (2003) 0.84
Expression of sulfotransferase isoform 1A1 (SULT1A1) in breast cancer cells significantly increases 4-hydroxytamoxifen-induced apoptosis. Int J Mol Epidemiol Genet (2010) 0.84
Tumorigenicity of chloral hydrate, trichloroacetic acid, trichloroethanol, malondialdehyde, 4-hydroxy-2-nonenal, crotonaldehyde, and acrolein in the B6C3F(1) neonatal mouse. Cancer Lett (2002) 0.83
Lactoperoxidase-catalyzed activation of carcinogenic aromatic and heterocyclic amines. Chem Res Toxicol (2004) 0.83
CYP2A6 activity determined by caffeine phenotyping: association with colorectal cancer risk. Cancer Epidemiol Biomarkers Prev (2002) 0.83
Examination of human tissue cytosols for expression of sulfotransferase isoform 1A2 (SULT1A2) using a SULT1A2-specific antibody. Mol Pharmacol (2004) 0.82
Association of SULT2A1 allelic variants with plasma adrenal androgens and prostate cancer in African American men. J Steroid Biochem Mol Biol (2006) 0.82
Human liver microsomal metabolism and DNA adduct formation of the tumorigenic pyrrolizidine alkaloid, riddelliine. Chem Res Toxicol (2003) 0.81
Potential role of UGT1A4 promoter SNPs in anastrozole pharmacogenomics. Drug Metab Dispos (2013) 0.81
Effect of feeding grape pomace on selected metabolic parameters associated with high fructose feeding in growing Sprague-Dawley rats. J Med Food (2011) 0.80
Ultraperformance liquid chromatography-tandem mass spectrometry method for biomonitoring cooked meat carcinogens and their metabolites in human urine. Anal Chem (2010) 0.79
Effects of the ADH3, CYP2E1, and GSTP1 genetic polymorphisms on their expressions in Caucasian lung tissue. Lung Cancer (2002) 0.79
Genetic variability in energy balance and pancreatic cancer risk in a population-based case-control study in Minnesota. Pancreas (2014) 0.78
Association between GSTM1 copy number, promoter variants and susceptibility to urinary bladder cancer. Int J Mol Epidemiol Genet (2012) 0.77
Fulvestrant up regulates UGT1A4 and MRPs through ERα and c-Myb pathways: a possible primary drug disposition mechanism. Springerplus (2013) 0.77
GSTM1 copy number and promoter haplotype as predictors for risk of recurrence and/or second primary tumor in patients with head and neck cancer. Pharmgenomics Pers Med (2013) 0.77